Newron Pharmaceuticals SpA (NWRN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Newron Pharmaceuticals SpA (NWRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10159
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Newron Pharmaceuticals SpA (Newron) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson’s disease. Newron’s other products in pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co., Ltd. It operates along with its subsidiaries in the UK, Sweden, Switzerland and the US. Newron is headquartered in Bresso, Milan, Italy.

Newron Pharmaceuticals SpA (NWRN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Newron Pharma Enters Into Co-Development Agreement With Zambon 11
Licensing Agreements 12
Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14
Equity Offering 16
Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16
Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17
Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18
Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19
Newron Pharma to Raise Funds through Public Offering of Shares 21
Newron Pharma Announces Private Placement Of Shares For US$21 Million 22
Newron Pharma Completes Private Placement Of Shares For US$4.8 Million 24
Acquisition 25
Newron Pharma Completes Acquisition Of NeuroNova For US$12 Million 25
Newron Pharmaceuticals SpA – Key Competitors 27
Newron Pharmaceuticals SpA – Key Employees 28
Newron Pharmaceuticals SpA – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Sep 13, 2018: Newron reports half-year 2018 results 30
Mar 01, 2018: Newron Announces 2017 Financial Results and Provides Outlook for 2018 32
Sep 14, 2017: Newron reports half-year 2017 results 35
Mar 02, 2017: Newron announces 2016 financial results and provides outlook for 2017 37
Corporate Communications 38
Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia 38
Product News 39
10/25/2017: Newron Pharmaceuticals to Present at European Rett Syndrome Congress and Host Advisory Board Meeting 39
07/11/2017: XADAGO (Safinamide) Now Available in the U.S. for Parkinson’s Disease Patients 40
05/12/2017: Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago (safinamide) 41
04/10/2017: Zambon Launches Xadago (Safinamide) In Portugal For Patients With Mid- To Late-Stage Parkinson’s Disease 42
03/21/2017: FDA approves drug to treat Parkinson’s disease 43
03/02/2017: Newron Provides Update on Sarizotan 44
03/02/2017: Newron Pharmaceuticals Provides Update on Xadago (safinamide) 45
02/08/2018: Newron Pharmaceuticals Announces Change in the Board of Directors 46
02/01/2018: Primary Endpoint Met In Phase II/III Clinical Study of Investigational Parkinson’s Disease Treatment Safinamide in Japan 47
Product Approvals 48
Jun 12, 2017: Zambon’s Xadago Rejects For Use Within NHS Scotland 48
Clinical Trials 49
Jun 13, 2018: Newron Provides Update on STARS Clinical Study with Sarizotan for the Treatment of Rett Syndrome 49
May 17, 2017: Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age 50
Other Significant Developments 51
Mar 27, 2018: Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018 51
Dec 11, 2017: Newron Provides End of Year Corporate Update 52
Nov 07, 2017: Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Newron Pharmaceuticals SpA, Deals By Therapy Area, 2012 to YTD 2018 9
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Newron Pharma Enters Into Co-Development Agreement With Zambon 11
Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14
Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16
Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17
Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18
Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19
Newron Pharma to Raise Funds through Public Offering of Shares 21
Newron Pharma Announces Private Placement Of Shares For US$21 Million 22
Newron Pharma Completes Private Placement Of Shares For US$4.8 Million 24
Newron Pharma Completes Acquisition Of NeuroNova For US$12 Million 25
Newron Pharmaceuticals SpA, Key Competitors 27
Newron Pharmaceuticals SpA, Key Employees 28
Newron Pharmaceuticals SpA, Subsidiaries 29

List of Figures
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Newron Pharmaceuticals SpA (NWRN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Synthos SA:企業の戦略的SWOT分析
    Synthos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Hillenbrand, Inc.:企業の戦略・SWOT・財務情報
    Hillenbrand, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hillenbrand, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Alliancebernstein Holding Lp
    Alliancebernstein Holding Lp - Strategy, SWOT and Corporate Finance Report Summary Alliancebernstein Holding Lp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • TriGranit Corporation:企業の戦略・SWOT・財務情報
    TriGranit Corporation - Strategy, SWOT and Corporate Finance Report Summary TriGranit Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • PerkinElmer Inc (PKI):企業の財務・戦略的SWOT分析
    PerkinElmer Inc (PKI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Franklin Covey Co. (FC):企業の財務・戦略的SWOT分析
    Franklin Covey Co. (FC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Axpo Holding AG-エネルギー分野:企業M&A・提携分析
    Summary Axpo Holding AG (Axpo) is an electricity utility that produces, trades and sells electricity. It is wholly owned by the cantons of Northeastern Switzerland. The company covers the entire value chain from power generation and marketing of a wide range of products to power distribution. It gen …
  • Siemens AG (SIE):石油・ガス:M&Aディール及び事業提携情報
    Summary Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution; oil and gas production and transportation; medical imagin …
  • Adecco Group AG :企業の戦略・SWOT・財務情報
    Adecco Group AG - Strategy, SWOT and Corporate Finance Report Summary Adecco Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Samsung C&T Corporation:企業の戦略・SWOT・財務情報
    Samsung C&T Corporation - Strategy, SWOT and Corporate Finance Report Summary Samsung C&T Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Genesco Inc.:企業の戦略・SWOT・財務情報
    Genesco Inc. - Strategy, SWOT and Corporate Finance Report Summary Genesco Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Guangshen Railway Company Limited:企業の戦略・SWOT・財務情報
    Guangshen Railway Company Limited - Strategy, SWOT and Corporate Finance Report Summary Guangshen Railway Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • American Financial Group, Inc.:企業の戦略・SWOT・財務情報
    American Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Lampsa Hotel Company
    Lampsa Hotel Company - Strategy, SWOT and Corporate Finance Report Summary Lampsa Hotel Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Landauer Inc (LDR):企業の財務・戦略的SWOT分析
    Summary Landauer Inc (Landauer), a subsidiary of Fortive Corp, is a medical device company that manufactures and distributes integrated radiation safety products. The company provides professional medical physics, occupational radiation monitoring, and medical products. Its products include dosimete …
  • Clientele Limited
    Clientele Limited - Strategy, SWOT and Corporate Finance Report Summary Clientele Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Biocare Medical LLC-医療機器分野:企業M&A・提携分析
    Summary Biocare Medical LLC (Biocare) develops and supplies automated immunohistochemistry instrumentation and reagents. The company offers androgen receptor, amyloid A, estrogen receptor, ERG, factor xlla and folate receptor alpha IHC assay kit, among others. It offers on-site training, technical s …
  • Bio-Rad Laboratories Inc (BIO):医療機器:M&Aディール及び事業提携情報
    Summary Bio-Rad Laboratories Inc (Bio-Rad) develops, manufactures and markets a range of products and systems for the life science research, healthcare, analytical chemistry and other markets. The company’s major products include reagents, apparatus, laboratory instruments, test systems, informatics …
  • Reed’s, Inc. (REED):企業の財務・戦略的SWOT分析
    Summary Reed's Inc (Reed) is manufacturer and distribution of non-alcoholic carbonated soft drinks, candies and beverages. The company's product portfolio include Reed's ginger brew, wellness ginger shots, zero sugar, and ginger candies It brews carbonated ginger in various flavors including extra g …
  • Envipco Holding NV (ENVI):企業の財務・戦略的SWOT分析
    Envipco Holding NV (ENVI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆